Drug intelligence / Profile preview

ADB-002

Development stage: Preclinical
Lead developer: AdaptBio Therapeutics
Modality: Peptides

Overview

ADB-002 is a peptide-based checkpoint inhibitor developed by AdaptBio Therapeutics using its proprietary ADAPTin platform. It is designed to target and inhibit the Programmed Cell Death Protein 1 (PD-1) receptor. By blocking the PD-1 signaling pathway, ADB-002 prevents the suppression of T-cell activity, thereby restoring and enhancing the immune system's ability to identify and destroy tumor cells. The drug is currently in preclinical development for the treatment of solid tumors, specifically melanoma and basal cell carcinoma (BCC).

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ADB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB-002.

Explore the full profile